How has AstraZeneca (LSE: AZN) performed against the market?
If the long-run return on the market is 9.4% (as researchers at Credit Suisse say), investing in shares should be a no-brainer. Somehow, however, all too often our portfolios don't seem to reflect that attractive performance.
This is partly because that 9.4% number is an average derived from 100 years of data. Picking various time periods within that 100 years gives very different outcomes -- and the market almost never actually returns 9.4% in any single year.
Needless to say, unless you're holding a market tracker, your portfolio could have dramatically different results than what the market experiences. If you own a disproportionate amount of winning shares, your returns could be significantly better than the market. On the other hand...
In this series of articles, I'm looking at how individual shares have performed against the FTSE 100 (UKX) during the past 10 years. Today, I'm assessing struggling pharmaceutical giant AstraZeneca (LSE: AZN) (NYSE: AZN.US).
Over the last decade, AstraZeneca's performance has lagged behind that of the FTSE 100.
Source: S&P Capital IQ
AstraZeneca's shares have struggled to keep up with the market over the past 10 years, posting an average annual return of 5.3%, which failed to match the FTSE 100's 7.2% return over the same period (these return calculations assume dividends were reinvested).
Despite trailing the market's performance for most of the past 10 years, it wasn't until 2009 that AstraZeneca started to look like a deal compared to the FTSE 100 in terms of price-to-earnings (P/E) multiples. Astra's P/E has averaged 14 over the past 10 years, but has been on a general downward trend as fears about its pending patent expiries have scared off investors.
Source: S&P Capital IQ and Thomson Reuters
But that's all history for AstraZeneca. The future -- as with every pharmaceutical company -- is in its pipeline. Unfortunately, as my colleague Maynard Paton points out in this video, the pipeline story at Astra isn't exactly inspiring as continued patent expiry and a dearth of new products mean investors can expect sales and earnings to stagnate over the next few years.
However, Astra continues to invest over $4 billion per year in researching the next big blockbuster and still pays out a well-covered dividend that is currently yielding over 6%. That is a pretty handsome payout to sit around waiting for Astra's labs to shout "Eureka!" sometime in the next few years.
Large caps for the long run
If AstraZeneca isn't for you, you can always consider the eight large caps for the long run spotlighted in "Super-Investor Neil Woodford's Favourite Blue Chips". This exclusive Fool report evaluates the FTSE shares the legendary index-trouncing investor is backing today, and the investing logic behind them.
You can read all about the potential long-run winners Mr Woodford currently favours by downloading the exclusive report today -- it's free!
> Nate does not own any share mentioned in this article.
